Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 11/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20253015 | 0.95 | FKBP1A (0.51) | FKBP1APOLB | |
| SCHEMBL7874672 | 0.86 | FKBP1A (0.64) | FKBP1APOLB | |
| SCHEMBL1774605 | 0.86 | FKBP1A (0.58) | FKBP1A | |
| SCHEMBL1775248 | 0.86 | FKBP1A (0.64) | FKBP1APOLB | |
| SCHEMBL2006947 | 0.81 | FKBP1A (0.58) | FKBP1APOLB | |
| SCHEMBL9650460 | 0.81 | FKBP1A (0.52) | FKBP1A | |
| SCHEMBL7434434 | 0.81 | FKBP1A (0.52) | FKBP1A | |
| SCHEMBL3154647 | 0.81 | FKBP1A (0.52) | FKBP1A | |
| SCHEMBL5833327 | 0.80 | FKBP1A (0.68) | FKBP1A | |
| SCHEMBL611148 | 0.80 | FKBP1A (0.68) | FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041019-A1 | PROTEASE INHIBITORS | SERPINB1, PREP, DNPEP | FKBP1A 1184/4885POLB 1065/4885CA12 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.